Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CSF3R T618I
Therapy Ruxolitinib
Indication/Tumor Type chronic neutrophilic leukemia
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CSF3R T618I chronic neutrophilic leukemia predicted - sensitive Ruxolitinib Case Reports/Case Series Actionable In a clinical case study, Jakafi (ruxolitinib) treatment resulted in symptom improvement and decreased spleen and liver size lasting 5 months in a patient with chronic neutrophilic leukemia harboring CSF3R T618I along with SETBP1 G870S (PMID: 27068405). 27068405
CSF3R T618I chronic neutrophilic leukemia predicted - sensitive Ruxolitinib Case Reports/Case Series Actionable In a Phase II trial, Jakafi (ruxolitinib) treatment resulted in an overall hematologic response rate of 35% (15/43, 4 complete and 11 partial responses) and a median overall survival of 18.8 months in patients with chronic neutrophilic leukemia (CNL) or atypical chronic myeloid leukemia harboring CSF3R mutations, including T618I (n=20), T640N (n=1), and T615A (n=1), with 2 complete and 9 partial responses in CNL patients harboring CSF3R T618I (PMID: 31880950; NCT02092324). 31880950
PubMed Id Reference Title Details
(31880950) Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. Full reference...
(27068405) Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. Full reference...